Overlapping area represents amount of risk that can be diversified away by holding Biovail Corp. Common Stoc and Nektar Therapeutics in the same portfolio (assuming nothing else is changed)
Valeant Pharmaceuticals International, Inc. raised bidding price from $6.50 to $7.50 per share in cash relevant to its earlier proposed price for the acquisition of ISTA Pharmaceuticals.
Hit with sliding profits, a weak late-stage pipeline and a troubling track record on clinical trials, AstraZeneca ($AZN) has decided to trigger another round of layoffs, with 2200 R&D staffers losing their jobs in this round.
NEW YORK (AVAFIN) -- Shares of Nektar Therapeutics closed above the 200-day moving average of $6.44 as of Wednesday. This development is a sign of bullishness as long as prices remain above the moving average.
USA 
Select Assests
Optimize Portfolio
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatilities
Import Equities
Search Equities
Filter Tops
Biovail Corp. Common Stoc and 
Nektar Therapeutics
Nektar Therapeutics
1.80% 
